LONDON (Alliance News) - Allergy Therapeutics PLC on Tuesday said it has received Clinical Trial Application approval in Spain for its phase I Acarovac clinical study.
The allergy-focused pharmaceutical company said its Acarovac product is the only house-dust mite immunotherapy in development using natural biodegradable microcrystalline tyrosine and monophosphoryl lipid A to treat perennial allergic rhinitis.
House dust mites are a major cause of perennial allergic rhinitis and allergic asthma, Allergy Therapeutics said.
As the application has been approved, Allergy Therapeutics said it expects its product to begin Phase I studied immediately, to assess the safety and tolerability of two different dose regimes, both of which will involve a two-to-four week initial up-dosing phase.
The 32-patient Phase I trial is expected to last one year and to be delivered on-time, in line with Allergy Therapeutics strategic plan and, if the trial is successful, the group expects to launch Acarovac in Spain on a named-patient basis, it said.
Shares in Allergy Therapeutics were up 3.4% at 25.34 pence on Tuesday morning.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2017 Alliance News Limited. All Rights Reserved.
Allergy Thera. (AGY)